The Arizona House of Representatives has approved a Senate-passed bill to legalize psilocybin service centers where people could receive the psychedelic in a medically supervised...

The Arizona House of Representatives has approved a Senate-passed bill to legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting.

Two days after clearing a final House committee, the legislation from Sen. T. J. Shope (R) was approved by the full chamber in a 42-16 vote on Friday. It now heads to the desk of Gov. Katie Hobbs (D).

If enacted into law, the Department of Human Services (DHS) would be authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could administer the psychedelic.

The legislation would significantly expand on Arizona’s existing research-focused psychedelics law that provides $5 million in annual funding to support studies into psilocybin therapy.

The proposal would establish an Arizona Psilocybin Advisory Board, comprised of members appointed by the governor and legislative leaders. Representatives of the attorney general’s office and DHS, as well as military veterans, first responders, scientists with experience with psilocybin and physicians would be among the members.

The board would be responsible for establishing training criteria for psilocybin service center staff, making recommendations on the implementation of the law, and studying the science and policy developments related to psychedelics.

By July 31, 2025 and each year after that, members would need to submit an annual report on the status of “medical, psychological and scientific” studies into the safety and efficacy of psilocybin, as well as a “long-term strategic plan” on ensuring that psychedelic-assisted therapy remains “safe, accessible and affordable” to people 21 and older.

Medical directors of psychedelic-assisted therapy centers would need to complete at least 132 hours of training under an approved program, which would need to involve lessons on the historical and traditional use of psychedelics, safety and ethics, facilitation skills and preparation, administration and integration.

The bill, which is cosponsored by Senate President Warren Petersen (R), states that DHS would need to start accepting applications for psychedelics centers by January 1, 2026. The department would need to promulgate rules for the program, but it would be barred from requiring specific eligible conditions for participation in psilocybin services.

Regulators could also license psilocybin centers that are carrying out clinical trials into the psychedelic that could lead to a Food and Drug Administration-approved drug.

Meanwhile, in January an Arizona House committee approved a separate bill to protect the $5 million in funding that’s already been designated for psilocybin research from being redistributed amid a state budget deficit.

The fund was enacted last year under an appropriations package signed by the governor that mandated research into the medical potential of psilocybin mushrooms for a variety of conditions.

Psilocybin Research Advisory Council that was established under DHS met for the first time last November prior an open application period for potential grant recipients.

The grant money must be distributed to applicants with proposals focused on clinical trials that are meant to identify therapeutic applications that could receive FDA approval for treatment of 13 listed conditions.

Arizona one of several states where lawmakers have worked to promote research into psychedelics amid growing public interest in expanding therapeutic access and ending criminalization.


Marijuana Moment is tracking more than 1,500 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

For example, bipartisan California lawmakers have filed legislation to authorize a pilot program that would provide psilocybin treatment to military veterans and first responders.

Last month, Vermont Gov. Phil Scott (R) signed a bill into law to create a psychedelic-assisted therapy working group that will make recommendations on whether and how the state should regulate legal access to substances such as psilocybin and MDMA.

Maryland Gov. Wes Moore (D) signed legislation last month to create a psychedelics task force responsible for studying possible regulatory frameworks for therapeutic access to substances such as psilocybin, mescaline and DMT. It would be charged specifically with ensuring “broad, equitable and affordable access to psychedelic substances” in the state.

Last month in Alaska lawmakers sent the governor a bill to create a state task force to study how to license and regulate psychedelic-assisted therapy in the event of federal approval of substances such as MDMA and psilocybin.

Indiana’s governor recently signed a bill that includes provisions to fund clinical research trials into psilocybin.

Utah’s governor, meanwhile, allowed a bill to authorize a pilot program for hospitals to administer psilocybin and MDMA as an alternative treatment option to become law without his signature.

Maine lawmakers sent the governor legislation to establish a commission tasked with studying and making recommendations on regulating access to psychedelic services.

A Connecticut joint legislative panel approved a bill to decriminalize possession of psilocybin.

The governor of New Mexico has endorsed a newly enacted resolution requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.

An Illinois committee also recently held a hearing to discuss a bill to legalize psilocybin and allow regulated access at service centers in the state where adults could use the psychedelic in a supervised setting—with plans to expand the program to include mescaline, ibogaine and DMT.

Lawmakers in Hawaii also considered a bill that would provide some legal protections to patients engaging in psilocybin-assisted therapy with a medical professional’s approval.

New York lawmakers said that a bill to legalize psilocybin-assisted therapy in that state has a “real chance” of passing this year.

A Nevada joint legislative committee held a hearing with expert and public testimony on the therapeutic potential of substances like psilocybin in January. Law enforcement representatives also shared their concerns around legalization—but there was notable acknowledgement that some reforms should be enacted, including possible rescheduling.

Youth Marijuana Use In Colorado Continues To Decline Since Legalization Took Effect, Contradicting Prohibitionist Fears

Image courtesy of Kristie Gianopulos.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Become a patron at Patreon!

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )